Summary
169.69 4.81(2.92%)05/16/2024
BeiGene Ltd (BGNE)
BeiGene Ltd (BGNE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.91 | 4.38 | 7.30 | 8.74 | -18.73 | -36.72 | 30.14 | 467.37 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 160.68 | |
| Open | 162.99 | |
| High | 164.40 | |
| Low | 158.21 | |
| Volume | 93,969 | |
| Change | -1.47 | |
| Change % | -0.91 | |
| Avg Volume (20 Days) | 199,070 | |
| Volume/Avg Volume (20 Days) Ratio | 0.47 | |
| 52 Week Range | 126.97 - 256.45 | |
| Price vs 52 Week High | -37.34% | |
| Price vs 52 Week Low | 26.55% | |
| Range | -1.42 | |
| Gap Up/Down | -1.83 | |
Fundamentals | ||
| Market Capitalization (Mln) | 17,971 | |
| EBIDTA | -678,579,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 431.45 | |
| Book Value | 35.9720 | |
| Earnings Per Share | -14.1740 | |
| EPS Estimate Current Quarter | -4.3700 | |
| EPS Estimate Next Quarter | -4.7200 | |
| EPS Estimate Current Year | -13.1000 | |
| EPS Estimate Next Year | -14.9500 | |
| Diluted EPS (TTM) | -14.1740 | |
| Revenues | ||
| Profit Marging | -1.2241 | |
| Operating Marging (TTM) | -1.2725 | |
| Return on asset (TTM) | -0.1557 | |
| Return on equity (TTM) | -0.3398 | |
| Revenue TTM | 1,062,403,968 | |
| Revenue per share TTM | 11.5800 | |
| Quarterly Revenue Growth (YOY) | 1.2670 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -1,056,660,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.3119 | |
| Revenue Enterprise Value | 23.8822 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 93,501,800 | |
| Shares Float | 55,616,127 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 20.26 | |
| Institutions (%) | 61.22 | |
05/14 16:01 EST - businesswire.com
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28 abstracts accepted at EHA2024, with four scheduled for oral presentations. “As part of our dedication to bringing high-quality therapies to patients around the world, our presen.
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28 abstracts accepted at EHA2024, with four scheduled for oral presentations. “As part of our dedication to bringing high-quality therapies to patients around the world, our presen.
05/08 06:00 EST - businesswire.com
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the first quarter 2024 and business highlights. “We are pleased to present another quarter of strong financial results. Supported by our tremendous global growth in revenue, we have now ascended into the top 15 of global oncology innovators based on total oncology sales. We also continue to make significant improvement in our operating leverage as w.
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced results from the first quarter 2024 and business highlights. “We are pleased to present another quarter of strong financial results. Supported by our tremendous global growth in revenue, we have now ascended into the top 15 of global oncology innovators based on total oncology sales. We also continue to make significant improvement in our operating leverage as w.
04/26 10:34 EST - businesswire.com
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company's strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets. This report comes at a time of tremendous growth for BeiGene. In 2023, the Company achieved the milestone of more than 1 million patients who wer.
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company's strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets. This report comes at a time of tremendous growth for BeiGene. In 2023, the Company achieved the milestone of more than 1 million patients who wer.
04/24 16:01 EST - businesswire.com
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year's ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that add.
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. “Our presentations at this year's ASCO highlight the strength of our growing oncology portfolio and our commitment to developing treatments that add.
04/23 06:00 EST - businesswire.com
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene's solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which.
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene's solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which.
03/14 16:28 EST - businesswire.com
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in.
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. TEVIMBRA will be available in the U.S. in.
03/14 14:17 EST - reuters.com
US FDA approves BeiGene's esophageal cancer therapy
The U.S. Food and Drug Administration has approved BeiGene's drug to treat a type of esophageal cancer in patients who have previously received chemotherapy.
US FDA approves BeiGene's esophageal cancer therapy
The U.S. Food and Drug Administration has approved BeiGene's drug to treat a type of esophageal cancer in patients who have previously received chemotherapy.
03/13 08:00 EST - businesswire.com
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lymp.
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced that the first doses of BRUKINSA® (zanubrutinib) have been administered for the treatment of adult patients with chronic lymp.
03/07 17:19 EST - businesswire.com
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy. The indication.
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), in combination with the anti-CD20 monoclonal antibody obinutuzumab, after two or more lines of systemic therapy. The indication.
03/07 15:50 EST - reuters.com
US FDA approves expanded use of BeiGene's blood cancer drug
The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.
US FDA approves expanded use of BeiGene's blood cancer drug
The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.
03/06 06:00 EST - businesswire.com
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting April 5-10 in San Diego. BeiGene has nine abstracts scheduled for poster presentations at AACR. “Our presentations at this year's AACR showcase our ongoing development of tislelizumab combinations in solid tumors.
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting April 5-10 in San Diego. BeiGene has nine abstracts scheduled for poster presentations at AACR. “Our presentations at this year's AACR showcase our ongoing development of tislelizumab combinations in solid tumors.
02/29 10:00 EST - businesswire.com
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials. The analysis suggests a progression-free survival and complete response advantage for.
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) based on data from the Phase 3 ALPINE and Phase 3 ASCEND trials. The analysis suggests a progression-free survival and complete response advantage for.
02/28 08:05 EST - businesswire.com
BeiGene to Present at Upcoming Investor Conferences
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:50 am ET; and Leerink Partners Global Biopharma Conference on Monday, March 11th, 2024 at 10:00 am ET Live webcasts of these events can be accessed from the investors.
BeiGene to Present at Upcoming Investor Conferences
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5th, 2024 at 9:50 am ET; and Leerink Partners Global Biopharma Conference on Monday, March 11th, 2024 at 10:00 am ET Live webcasts of these events can be accessed from the investors.
02/27 06:00 EST - businesswire.com
BeiGene's Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for TEVIMBRA® (tislelizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) aden.
BeiGene's Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for TEVIMBRA® (tislelizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) aden.
02/26 06:00 EST - businesswire.com
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today reinforced its continued global expansion, rapid global and U.S. revenue growth, and innovative R&D strategy with the presentation of results from the fourth quarter and full year 2023 and business highlights. “BeiGene made great progress in the fourth quarter and full year 2023 toward our goal to become an impactful next-generation oncol.
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today reinforced its continued global expansion, rapid global and U.S. revenue growth, and innovative R&D strategy with the presentation of results from the fourth quarter and full year 2023 and business highlights. “BeiGene made great progress in the fourth quarter and full year 2023 toward our goal to become an impactful next-generation oncol.
02/26 05:00 EST - businesswire.com
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications: In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-li.
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications: In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-li.
02/13 12:58 EST - investorplace.com
Get Rich Quick With These 3 Biotech Stocks to Buy Now
I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.
Get Rich Quick With These 3 Biotech Stocks to Buy Now
I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.
01/26 08:25 EST - seekingalpha.com
BeiGene: Debating On Finally Establishing A Position
The company's recent pipeline advancements and successful clinical trials have reduced its valuation and made it more attractive.
BeiGene: Debating On Finally Establishing A Position
The company's recent pipeline advancements and successful clinical trials have reduced its valuation and made it more attractive.
01/23 06:00 EST - businesswire.com
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board. Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016. “Dr. Brandicourt brings a wealth of global experience as we expand the perspective of BeiGene's Board of Directo.
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board. Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016. “Dr. Brandicourt brings a wealth of global experience as we expand the perspective of BeiGene's Board of Directo.
01/15 06:30 EST - fool.com
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
Biotech has been out of favor among investors for over two years. The sector could be on the verge of a trend reversal because of multiple tailwinds.
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
Biotech has been out of favor among investors for over two years. The sector could be on the verge of a trend reversal because of multiple tailwinds.